LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 227

Search options

  1. Article ; Online: Alzheimer's and Dementia Guidelines and Tables.

    Schneider, Lon S

    Psychopharmacology bulletin

    2023  Volume 53, Issue 2, Page(s) 8–65

    Abstract: Introduction The purpose of this guide is to provide convenient and useful information on about Alzheimer's disease and dementias of late life. The information includes selected facts, diagnostic criteria tables, descriptions of selected tests and ... ...

    Abstract Introduction The purpose of this guide is to provide convenient and useful information on about Alzheimer's disease and dementias of late life. The information includes selected facts, diagnostic criteria tables, descriptions of selected tests and screens, guidelines, clinical pharmacological data and references. This guide is divided into several sections: Background factsDiagnostic aids and criteria for dementia diagnosesMedications used for Alzheimer's disease and dementia Basic information on marketed treatments is provided although the treatment may not be FDA approved for this use. Approved cholinesterase inhibitors, memantine, and monoclonal antibodies are listed. No treatment is recommended or endorsed, however. This guide does not address the evidence base for the efficacy of the treatments listed.
    MeSH term(s) Humans ; Alzheimer Disease ; Antipsychotic Agents ; Depressive Disorder, Major ; Hallucinations ; Memantine
    Chemical Substances Antipsychotic Agents ; Memantine (W8O17SJF3T)
    Language English
    Publishing date 2023-07-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 4113-0
    ISSN 2472-2448 ; 0048-5764 ; 0376-0162
    ISSN (online) 2472-2448
    ISSN 0048-5764 ; 0376-0162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: What the Gantenerumab Trials Teach Us about Alzheimer's Treatment.

    Schneider, Lon S

    The New England journal of medicine

    2023  Volume 389, Issue 20, Page(s) 1918–1920

    MeSH term(s) Humans ; Alzheimer Disease/drug therapy ; Amyloid beta-Peptides ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use
    Chemical Substances Amyloid beta-Peptides ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; gantenerumab (4DF060P933)
    Language English
    Publishing date 2023-11-21
    Publishing country United States
    Document type Editorial
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMe2310903
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.

    Schneider, Lon S

    The American journal of psychiatry

    2022  Volume 179, Issue 8, Page(s) 519–521

    MeSH term(s) Antipsychotic Agents/adverse effects ; Dementia/drug therapy ; Humans ; Parkinson Disease/drug therapy ; Piperidines/adverse effects ; Psychotic Disorders/drug therapy ; Urea/analogs & derivatives
    Chemical Substances Antipsychotic Agents ; Piperidines ; Urea (8W8T17847W) ; pimavanserin (JZ963P0DIK)
    Language English
    Publishing date 2022-08-03
    Publishing country United States
    Document type Editorial
    ZDB-ID 280045-7
    ISSN 1535-7228 ; 0002-953X
    ISSN (online) 1535-7228
    ISSN 0002-953X
    DOI 10.1176/appi.ajp.20220519
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Pragmatic Trials and Repurposed Drugs for Alzheimer Disease.

    Schneider, Lon S

    JAMA neurology

    2019  Volume 77, Issue 2, Page(s) 162–163

    MeSH term(s) Alzheimer Disease/drug therapy ; Humans ; Minocycline
    Chemical Substances Minocycline (FYY3R43WGO)
    Language English
    Publishing date 2019-11-18
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2702023-X
    ISSN 2168-6157 ; 2168-6149
    ISSN (online) 2168-6157
    ISSN 2168-6149
    DOI 10.1001/jamaneurol.2019.3784
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The risks and uses of dietary supplements.

    Schneider, Lon S

    The Lancet. Neurology

    2019  Volume 18, Issue 9, Page(s) 814

    MeSH term(s) Dietary Supplements
    Language English
    Publishing date 2019-08-20
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2079704-7
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(19)30293-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Pimavanserin for patients with Alzheimer's disease psychosis.

    Schneider, Lon S

    The Lancet. Neurology

    2018  Volume 17, Issue 3, Page(s) 194–195

    MeSH term(s) Alzheimer Disease ; Double-Blind Method ; Humans ; Piperidines ; Psychotic Disorders ; Urea/analogs & derivatives
    Chemical Substances Piperidines ; Urea (8W8T17847W) ; pimavanserin (JZ963P0DIK)
    Language English
    Publishing date 2018-02-13
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2079704-7
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(18)30052-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book: Developments in geriatric psychiatry

    Schneider, Lon S.

    (New directions for mental health services ; 76)

    1997  

    Author's details Lon S. Schneider, ed
    Series title New directions for mental health services ; 76
    Collection
    Keywords Mental Disorders / in old age ; Mental Health Services ; Health Services for the Aged ; Alter ; Psychische Störung ; Senile Demenz
    Subject Altersdemenz ; Dementia senilis ; Altersverwirrtheit ; Altersverwirrung ; Alter ; Greisenalter ; Altersschwachsinn ; Altersblödsinn ; Seelische Störung ; Mental disorder ; Psychische Krankheit ; Seelische Krankheit ; Psychiatrische Krankheit ; Psychische Erkrankung ; Psychische Störungen ; Alter Mensch ; Betagter ; Senioren ; Senior
    Language English
    Size 136 S.
    Publisher Jossey-Bass
    Publishing place San Francisco
    Publishing country United States
    Document type Book
    HBZ-ID HT008357359
    ISBN 0-7879-9878-8 ; 978-0-7879-9878-3
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  8. Article ; Online: Dementia research priorities-1 - Author's reply.

    Schneider, Lon S

    The Lancet. Neurology

    2017  Volume 16, Issue 3, Page(s) 181

    MeSH term(s) Dementia ; Humans ; Research
    Language English
    Publishing date 2017-02-15
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2079704-7
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(17)30019-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Dementia research priorities-2 - Author's reply.

    Schneider, Lon S

    The Lancet. Neurology

    2017  Volume 16, Issue 3, Page(s) 182

    MeSH term(s) Dementia ; Humans ; Research
    Language English
    Publishing date 2017-02-15
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2079704-7
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(17)30018-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials.

    Goldberg, Terry E / Lee, Seonjoo / Devanand, Davangere P / Schneider, Lon S

    Journal of neurology, neurosurgery, and psychiatry

    2023  Volume 95, Issue 1, Page(s) 2–7

    Abstract: Background: Per cent slowing of decline is frequently used as a metric of outcome in Alzheimer's disease (AD) clinical trials, but it may be misleading. Our objective was to determine whether per cent slowing of decline or Cohen's d is the more valid ... ...

    Abstract Background: Per cent slowing of decline is frequently used as a metric of outcome in Alzheimer's disease (AD) clinical trials, but it may be misleading. Our objective was to determine whether per cent slowing of decline or Cohen's d is the more valid and informative measure of efficacy.
    Methods: Outcome measures of interest were per cent slowing of decline; Cohen's d effect size and number-needed-to-treat (NNT). Data from a graphic were used to model the inter-relationships among Cohen's d, placebo decline in raw score units and per cent slowing of decline with active treatment. NNTs were computed based on different magnitudes of d. Last, we tabulated recent AD anti-amyloid clinical trials that reported per cent slowing and for which we computed their respective d's and NNTs.
    Results: We demonstrated that d and per cent slowing were potentially independent. While per cent slowing of decline was dependent on placebo decline and did not include variance in its computation, d was dependent on both group mean difference and pooled SD. We next showed that d was a critical determinant of NNT, such that NNT was uniformly smaller when d was larger. In recent AD associated trials including those focused on anti-amyloid biologics, d's were below 0.23 and thus considered small, while per cent slowing was in the 22-29% range and NNTs ranged from 14 to 18.
    Conclusions: Standardised effect size is a more meaningful outcome than per cent slowing of decline because it determines group overlap, which can directly influence NNT computations, and yield information on the likelihood of minimum clinically important differences. In AD, greater use of effect sizes, NNTs, rather than relative per cent slowing, will improve the ability to interpret clinical trial results and evaluate the clinical meaningfulness of statistically significant results.
    MeSH term(s) Humans ; Alzheimer Disease/drug therapy ; Clinical Trials as Topic
    Language English
    Publishing date 2023-12-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 3087-9
    ISSN 1468-330X ; 0022-3050
    ISSN (online) 1468-330X
    ISSN 0022-3050
    DOI 10.1136/jnnp-2023-331941
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top